Please login to the form below

Not currently logged in
Email:
Password:

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in testing for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), as

Latest news

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    lymphoma (DLBCL) and according to Celgene could become a $3bn product if approved in multiple blood cancer indications.

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    Novartis gets speedy reviews for new Kymriah filings. US and EU regulatory agencies will review the drug for DLBCL patients. ... well as in adults with relapsed or refractory DLBCL who are ineligible for ASCT.

  • CAR-T therapies show long-term benefits in lymphoma CAR-T therapies show long-term benefits in lymphoma

    tisagenlecleucel) in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), helped laid to rest doubts that CAR-T can provide sustainable cancer responses. ... Kymriah was approved by the US FDA in August for acute lymphoblastic

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... As in the US, Novartis is filing for approval in children and young adults with relapsed/refractory ALL and in adults with relapsed/refractory

  • Novartis moves swiftly with lymphoma filing for CAR-T Kymriah Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

    Now, Novartis wants to extend its use into relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common forms of non-Hodgkin’s lymphoma (NHL). ... whose lymphoma had progressed despite first-line therapy and were ineligible for an

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics